It’s time to start the week off right with a breakdown of the biggest pre-market stock movers for Monday morning!
Moving stocks this morning are clinical trial results from several companies, a bankruptcy filing, as well as a tease of upcoming news.
Let’s get into that news below!
Pre-蜜桃传媒 Stock Movers: 10 Top Gainers
- Forza X1 (NASDAQ:FRZA) stock is rocketing close to 97% after over the weekend.
- Chijet Motor (NASDAQ:CJET) shares are soaring 65% following its .
- Evaxion Biotech (NASDAQ:EVAX) stock is surging nearly 44% alongside .
- Day One Biopharmaceutical (NASDAQ:DAWN) shares are rising more than 29% alongside .
- Golden Minerals (NYSEMKT:AUMN) stock is gaining over 21% after .
- MultiMetaVerse (NASDAQ:MMV) shares are increasing more than 20% following a .
- Immunogen (NASDAQ:IMGN) stock is rising over 16% .
- Dunxin Financial (NYSEMKT:DXF) shares are climbing more than 16% on Monday morning.
- Kaspien (NASDAQ:KSPN) stock is jumping over 15% today.
- Sentage (NASDAQ:SNTG) shares are up more than 15% without any clear news this morning.
10 Top Losers
- Mallinckrodt (NYSEMKT:MNK) stock is diving over 22% alongside from senior note holders.
- Yunji (NASDAQ:YJ) shares are tumbling more than 18% as it .
- Cyxtera Technologies (NASDAQ:CYXT) stock is taking an over 13% beating as it .
- Minerva Surgical (NASDAQ:UTRS) shares are sliding almost 12% following a Friday rally.
- Marker Therapeutics (NASDAQ:MRKR) stock is dropping more than 11% on no apparent news this morning.
- Kaixin Auto (NASDAQ:KXIN) shares are decreasing over 11% without any obvious news on Monday morning.
- Bluejay Diagnostics (NASDAQ:BJDX) stock is falling more than 9% in early morning trading today.
- Panbela Therapeutics (NASDAQ:PBLA) shares are declining over 9% after on Friday.
- Connect Biopharma (NASDAQ:CNTB) stock is slipping more than 9% this morning.
- Affimed (NASDAQ:AFMD) shares close out our pre-market stock movers down close to 9% after .
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
